Urotensin II in Chronic Kidney Diseases and Kidney Transplants

June 12, 2013 updated by: Mehmet Hursitoglu, Vakif Gureba Training and Research Hospital

Urotensin II in Chronic Kidney Diseases

The investigators are planning to study the serum level of Urotensin II in chronic kidney disease patients, kidney transplants, and healthy controls.

Study Overview

Status

Completed

Conditions

Detailed Description

The investigators will determine the urotensin II levels in Chronic kidney disease patients, kidney transplants, and healthy controls.

Study Type

Observational

Enrollment (Actual)

110

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey, 34100
        • Vakif Gureba Training & Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Healthy controls,CRF patients and kidney transplants aged more than 18

Description

Inclusion Criteria:

  • Age more than 18

Exclusion Criteria:

  • Inability to give a written consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Control
Healthy controls
Chronic kidney disease-1
Chronic kidney disease not taking dialysis treatment
Kidney Transplant
Kidney transplants

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
serum Urotensin II(UII)level
Time Frame: at enrollment
We tried to compare UII level in normal, chronic kidney disease and kidney transplant patients group
at enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Vakif Gureba Training and Research Hospital

Investigators

  • Study Director: Tufan Tukek, MD, Vakif Gureba Training & Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2010

Primary Completion (Actual)

July 1, 2010

Study Completion (Actual)

July 1, 2010

Study Registration Dates

First Submitted

April 2, 2010

First Submitted That Met QC Criteria

April 2, 2010

First Posted (Estimate)

April 5, 2010

Study Record Updates

Last Update Posted (Estimate)

June 13, 2013

Last Update Submitted That Met QC Criteria

June 12, 2013

Last Verified

June 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Dahiliye-2-Urotensin

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Renal Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe